- Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. LoRusso, P.M., Gadgeel, S.M., Wozniak, A., Barge, A.J., Jones, H.K., DelProposto, Z.S., DeLuca, P.A., Evelhoch, J.L., Boerner, S.A., Wheeler, C. Invest. New. Drugs (2008)